Genmab Announces New Phase III Combination Study of Daratumumab in Multiple Myeloma
(WorldNews Denmark)

Company Announcement Phase III study of daratumumab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma Collaborative study between European Myeloma Network and Janssen Study expected to start Q2 2017 Copenhagen, Denmark; April 28, 2017 -Genmab A/S (OMX: GEN) announced today that Janssen Research & Development, LLC, in collaboration with the European Myeloma Network (EMN) and Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), plans to start a Phase III study of daratumumab in relapsed and refractory multiple myeloma. The study (MMY3013, APOLLO) is a randomized Phase III that will compare daratumumab in combination with pomalidomide and...